SVB Securities analyst Daina Graybosch raised the firm’s price target on Innate Pharma (IPHA) to $10 from $9 and keeps an Outperform rating on the shares. SVB Securities is "pleased" by the partnership with Takeda (TAK) to develop ADCs for Celiac disease, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IPHA: